Innovative Psychedelics Pioneers Ketamine Therapy for Chronic Pain Amid Growing Demand

Ketamine therapy, traditionally known for its use in treating severe depression and mood disorders, is now being explored as a viable treatment for chronic pain by Innovative Psychedelics. Despite the lack of FDA approval for this specific use, the clinic is pushing forward with its commitment to innovative treatments that challenge conventional medical practices. Dr. Khare, a board-certified emergency physician at the clinic, emphasizes the potential of ketamine to transform the lives of those suffering from chronic pain, despite acknowledging the risks of side effects such as high blood pressure and nausea.

The clinic's approach involves a meticulously designed treatment protocol, featuring a 3-hour infusion administered once a month. This method aims to significantly mitigate the debilitating effects of chronic pain on patients' daily lives. Innovative Psychedelics has tailored its protocols to include higher doses of ketamine to enhance therapeutic outcomes, a strategy that, while effective, necessitates close supervision by experienced medical professionals to manage the increased risk of adverse effects.

Beyond ketamine, Innovative Psychedelics also offers Spravato treatments for depression and pain, further diversifying its portfolio of psychedelic-based therapies. The clinic enhances patient experience by providing easy access to bills and records through its patient portal, streamlining the administrative side of treatment. This initiative reflects the growing recognition of psychedelics' potential in addressing complex health issues, marking a significant shift in the landscape of mental health and pain management therapies.